Form 4: Director Dyrness Disposes SONN Shares Post-Merger

Sonnet BioTherapeutics Director Albert D. Dyrness reported the disposal of 4,537 common shares following the company's merger into Hyperliquid Strategies Inc.

Summary

• Albert D. Dyrness, a Director of Sonnet BioTherapeutics Holdings, Inc. (SONN), reported the disposal of 4,537 shares of Common Stock.
• The transaction occurred on December 2, 2025, pursuant to a Business Combination Agreement (BCA) dated July 11, 2025.
• Under the BCA, Sonnet BioTherapeutics Holdings, Inc. merged with and into TBS Merger Sub Inc, with Sonnet surviving as a direct wholly-owned subsidiary of Hyperliquid Strategies Inc (HSI).
• The disposed shares included 4,000 restricted stock units (RSUs) granted on July 11, 2025, which vested at the effective time of the Company Merger, and 537 vested RSUs held by the reporting person.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• Following this transaction, Albert D. Dyrness beneficially owns 0 shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock.
• All reported amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of an insider transaction resulting from a corporate merger. It does not inherently convey positive or negative sentiment regarding the company's operational or financial performance, but rather the mechanics of a significant corporate event.

Positives

• The vesting of 4,537 restricted stock units for Director Albert D. Dyrness, including 4,000 granted on July 11, 2025, indicates a successful compensation event for the insider.
• The completion of the Business Combination Agreement signifies a strategic milestone for Sonnet BioTherapeutics, transitioning it into a wholly-owned subsidiary of Hyperliquid Strategies Inc.

Negatives

• No direct negatives are identified within this Form 4 filing, which primarily reports a mandatory insider transaction resulting from a corporate event.

Risks

• No specific risks are detailed in this Form 4 filing, as it focuses on an insider transaction rather than operational or financial risk factors.

Future Outlook

This filing does not provide specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction beyond the completion of the merger.

Industry Context

The merger of Sonnet BioTherapeutics into Hyperliquid Strategies Inc. reflects ongoing consolidation and strategic realignments within the biotechnology and pharmaceutical sectors, where companies often seek to combine assets or integrate into larger entities to leverage synergies or access broader resources.

Corporate Governance

Related Party Transactions

• The transaction involves the conversion of a director's (Albert D. Dyrness) equity compensation (restricted stock units) into shares of the acquiring entity (Hyperliquid Strategies Inc.) and Contingent Value Rights as part of a Business Combination Agreement.

Stakeholder Impact

• Shareholders of Sonnet BioTherapeutics Holdings, Inc. have had their equity converted into shares of Hyperliquid Strategies Inc. and Contingent Value Rights, fundamentally changing their investment vehicle and potential future returns.
• The merger impacts employees and management of Sonnet BioTherapeutics as the company integrates into a larger corporate structure under Hyperliquid Strategies Inc.

Key Dates

Keywords

Sonnet BioTherapeutics, Hyperliquid Strategies Inc, SONN, Insider Transaction, Form 4, Merger, Business Combination Agreement, Restricted Stock Units, Director Share Disposal, Equity Exchange, CVR